An Act to amend and reenact § 18.2-251.5 of the Code of Virginia, relating to manufacturing, selling, giving, distributing, or possessing medetomidine; penalties.
HB1103 amends Virginia’s controlled-substance-related penalty statute for medetomidine and xylazine. The bill makes it a Class 5 felony to knowingly manufacture, sell, give, distribute, or possess with intent to manufacture, sell, give, or distribute either substance when intended for human consumption. It also makes simple knowing possession of either substance for human consumption a Class 1 misdemeanor.
The bill preserves explicit exceptions for legitimate veterinary use. It does not criminalize manufacturing, selling, distributing, possessing, administering, prescribing, or dispensing medetomidine or xylazine when done in good faith for animals within legitimate veterinary practice, including possession or administration under a valid veterinarian prescription. The act also includes a fiscal-impact statement noting it may increase incarceration or juvenile commitment costs, with a minimum fiscal impact assigned because the exact amount cannot be determined.
HB1103 directly amends § 18.2-251.5 of the Code of Virginia, expanding the statute to cover medetomidine in addition to xylazine and reinforcing criminal penalties tied to human consumption. It creates or confirms felony and misdemeanor liability for trafficking and possession of these substances outside veterinary contexts, while preserving lawful veterinary activity as an exception. The bill may increase state correctional and juvenile justice costs due to potential new prosecutions and commitments.
No committee transcripts or recorded votes were provided, so there is no documented debate or roll-call sentiment in the supplied materials. Based on the enacted text, the bill appears to reflect a public-safety and drug-control approach, with a clear carveout for veterinary professionals and animal treatment uses. The absence of recorded opposition or support in the provided context limits any stronger conclusion about legislative sentiment.
The main point of contention likely concerns balancing drug enforcement against legitimate veterinary use. Supporters would be expected to favor the bill as a response to misuse of medetomidine and xylazine in human consumption, while potential critics might focus on the breadth of criminal penalties or the risk of unintended impacts on animal-care practices. The statute’s explicit veterinary exceptions appear designed to address that concern by protecting licensed and good-faith animal treatment uses.